Powering a New Wave of Immune Therapeutics

At Sonnet BioTherapeutics, we are taking the fight directly to cancer. Our proprietary FHAB™ (Fully Human Albumin Binding) technology empowers the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms.

About Sonnet BioTherapeutics
Technology Platform

Technology Platform

Our FHAB platform utilizes a fully human single-chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues.

Technology Platform
Pipeline

Pipeline

Our clinical-stage pipeline comprises five cytokine-derived therapeutic candidates, with a lead compound ready to enter Phase 2 development.

Pipeline
Leadership

Leadership

The Sonnet team combines technical expertise in cytokine biology, as well as extensive experience in drug discovery and development.

Team

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today